Evidence map›Paper›PMID 23730303›Full record

ArticleFrontiers in immunology2013

Arginase promotes skeletal muscle arteriolar endothelial dysfunction in diabetic rats.

Fruzsina K Johnson, Robert A Johnson, Kelly J Peyton, Ahmad R Shebib, William Durante

Abstract read
In one paragraph

Article in Frontiers in immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. HInternational journal of molecular sciences · 2022
    Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Novel therapeutic strategies for adult obese asthmatics.Immunology and allergy clinics of North America · 2014
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fruzsina K JohnsonDepartment of Physiology and Pharmacology, Lincoln Memorial University Harrogate, TN, USA.
Robert A Johnson
Kelly J Peyton
Ahmad R Shebib
William Durante

Funding

CARBON MONOXIDE AND VASCULAR SMOOTH MUSCLE CELL FUNCTIONR01HL059976 · NHLBI · UNIVERSITY OF MISSOURI-COLUMBIA · PI DURANTE, WILLIAM · 1999 to 2013
$3.3M
ARGINASE AND ARTERIAL INJURYR01HL074966 · NHLBI · UNIVERSITY OF MISSOURI-COLUMBIA · PI DURANTE, WILLIAM · 2005 to 2009
$1.6M
Heme oxygenase and hemorrhagic circulatory collapseR01HL076187 · NHLBI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI JOHNSON, ROBERT A. · 2004 to 2007
$1.2M
NHLBI NIH HHS R01 HL059976NHLBI NIH HHS R01 HL074966NHLBI NIH HHS R01 HL076187
6 · The paper itself

Abstract

Endothelial dysfunction is a characteristic feature in diabetes that contributes to the development of vascular disease. Recently, arginase has been implicated in triggering endothelial dysfunction in diabetic patients and animals by competing with endothelial nitric oxide synthase for substrate l-arginine. While most studies have focused on the coronary circulation and large conduit blood vessels, the role of arginase in mediating diabetic endothelial dysfunction in other vascular beds has not been fully investigated. In the present study, we determined whether arginase contributes to endothelial dysfunction in skeletal muscle arterioles of diabetic rats. Diabetes was induced in male Sprague Dawley rats by streptozotocin injection. Four weeks after streptozotocin administration, blood glucose, glycated hemoglobin, and vascular arginase activity were significantly increased. In addition, a significant increase in arginase I and II mRNA expression was detected in gracilis muscle arterioles of diabetic rats compared to age-matched, vehicle control animals. To examine endothelial function, first-order gracilis muscle arterioles were isolated, cannulated in a pressure myograph system, exposed to graded levels of luminal flow, and internal vessel diameter measured. Increases in luminal flow (0-50 μL/min) caused progressive vasodilation in arterioles isolated from control, normoglycemic animals. However, flow-induced vasodilation was absent in arterioles obtained from streptozotocin-treated rats. Acute in vitro pretreatment of blood vessels with the arginase inhibitors N (ω)-hydroxy-nor-l-arginine or S-(2-boronoethyl)-l-cysteine restored flow-induced responses in arterioles from diabetic rats and abolished differences between diabetic and control animals. Similarly, acute in vitro pretreatment with l-arginine returned flow-mediated vasodilation in vessels from diabetic animals to that of control rats. In contrast, d-arginine failed to restore flow-induced dilation in arterioles isolated from diabetic animals. Administration of sodium nitroprusside resulted in a similar degree of dilation in arterioles isolated from control or diabetic rats. In conclusion, the present study identifies arginase as an essential mediator of skeletal muscle arteriolar endothelial dysfunction in diabetes. The ability of arginase to induce endothelial dysfunction in skeletal muscle arterioles may further compromise glucose utilization and facilitate the development of hypertension in diabetes.

Indexed as

arginaseargininediabetesendothelial dysfunctionflow-mediated vasodilation

Identifiers

PMID23730303
PMCPMC3657690

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.